More Than Just Humira: US Biosimilars Enjoy An Eventful 2023

Adalimumab Competition Hits, Firms Settle On Stelara And New Biosimilars Approved

 
• By Dave Wallace

The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.  

Ariel view of US from space lit up at night
• Source: Shutterstock

In 2023, one story dominated the headlines for the US biosimilars sector: the debut of biosimilar competition to AbbVie Inc.’s top-selling Humira (adalimumab) immunology brand.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo